Medical Properties Trust Valuation
Is MPW * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MPW * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MPW * (MX$79) is trading below our estimate of fair value (MX$123.3)
Significantly Below Fair Value: MPW * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MPW *?
Other financial metrics that can be useful for relative valuation.
What is MPW *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$2.73b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 14.2x |
Enterprise Value/EBITDA | 29.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MPW *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 10.7x | ||
TERRA 13 FIBRA Terrafina | 7.8x | 3.9% | Mex$33.3b |
FSITES 20 Fideicomiso Opsimex | 13.5x | n/a | Mex$88.1b |
EDUCA 18 Fideicomiso Irrevocable No. F/3277 en Banco Invex S. A. Institución de Banca Múltiple INVEX Grupo | 16.2x | 3.5% | Mex$66.3b |
DANHOS 13 Fibra Danhos | 5.2x | 4.2% | Mex$32.7b |
MPW * Medical Properties Trust | 3.1x | 5.1% | Mex$2.7b |
Price-To-Sales vs Peers: MPW * is good value based on its Price-To-Sales Ratio (3.1x) compared to the peer average (9.7x).
Price to Earnings Ratio vs Industry
How does MPW *'s PE Ratio compare vs other companies in the Global Health Care REITs Industry?
Price-To-Sales vs Industry: MPW * is good value based on its Price-To-Sales Ratio (3.1x) compared to the Global Health Care REITs industry average (6.9x).
Price to Sales Ratio vs Fair Ratio
What is MPW *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.1x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MPW *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$79.00 | Mex$84.90 +7.5% | 18.2% | Mex$119.95 | Mex$68.54 | n/a | 10 |
Apr ’25 | Mex$77.00 | Mex$77.31 +0.4% | 29.4% | Mex$118.66 | Mex$33.90 | n/a | 9 |
Mar ’25 | Mex$76.81 | Mex$76.67 -0.2% | 28.5% | Mex$119.13 | Mex$34.04 | n/a | 10 |
Feb ’25 | Mex$57.00 | Mex$90.47 +58.7% | 42.1% | Mex$171.59 | Mex$34.32 | n/a | 11 |
Jan ’25 | Mex$85.00 | Mex$119.92 +41.1% | 45.1% | Mex$256.98 | Mex$68.53 | n/a | 11 |
Dec ’24 | Mex$82.20 | Mex$119.92 +45.9% | 45.1% | Mex$256.98 | Mex$68.53 | n/a | 11 |
Nov ’24 | Mex$90.00 | Mex$148.34 +64.8% | 38.9% | Mex$270.45 | Mex$72.12 | n/a | 11 |
Oct ’24 | Mex$94.30 | Mex$162.78 +72.6% | 26.5% | Mex$263.33 | Mex$105.33 | n/a | 11 |
Sep ’24 | n/a | Mex$164.70 0% | 23.1% | Mex$256.37 | Mex$119.64 | n/a | 11 |
Aug ’24 | Mex$170.00 | Mex$195.28 +14.9% | 23.3% | Mex$301.29 | Mex$150.64 | n/a | 12 |
Jul ’24 | n/a | Mex$198.21 0% | 24.3% | Mex$308.02 | Mex$136.90 | n/a | 12 |
Jun ’24 | Mex$150.00 | Mex$203.90 +35.9% | 25.3% | Mex$321.14 | Mex$142.73 | n/a | 14 |
May ’24 | Mex$139.00 | Mex$211.30 +52.0% | 26.1% | Mex$322.71 | Mex$143.43 | n/a | 14 |
Apr ’24 | Mex$145.00 | Mex$226.78 +56.4% | 24.6% | Mex$324.40 | Mex$144.18 | Mex$77.00 | 12 |
Mar ’24 | Mex$191.00 | Mex$264.62 +38.5% | 15.7% | Mex$329.37 | Mex$182.98 | Mex$76.81 | 13 |
Feb ’24 | Mex$236.00 | Mex$288.60 +22.3% | 15.2% | Mex$337.67 | Mex$187.59 | Mex$57.00 | 13 |
Jan ’24 | n/a | Mex$303.74 0% | 18.4% | Mex$373.25 | Mex$196.45 | Mex$85.00 | 13 |
Dec ’23 | n/a | Mex$316.81 0% | 14.0% | Mex$363.96 | Mex$191.56 | Mex$82.20 | 13 |
Nov ’23 | n/a | Mex$330.45 0% | 15.3% | Mex$395.93 | Mex$197.96 | Mex$90.00 | 13 |
Oct ’23 | Mex$250.00 | Mex$361.89 +44.8% | 11.8% | Mex$458.77 | Mex$299.20 | Mex$94.30 | 14 |
Sep ’23 | n/a | Mex$372.36 0% | 10.9% | Mex$460.07 | Mex$300.05 | n/a | 13 |
Aug ’23 | n/a | Mex$401.79 0% | 16.9% | Mex$548.29 | Mex$304.60 | Mex$170.00 | 14 |
Jul ’23 | Mex$320.00 | Mex$439.49 +37.3% | 15.2% | Mex$542.90 | Mex$301.61 | n/a | 14 |
Jun ’23 | n/a | Mex$448.32 0% | 11.7% | Mex$536.28 | Mex$357.52 | Mex$150.00 | 14 |
May ’23 | n/a | Mex$479.60 0% | 10.5% | Mex$551.03 | Mex$387.77 | Mex$139.00 | 14 |
Apr ’23 | n/a | Mex$485.81 0% | 7.9% | Mex$536.11 | Mex$377.26 | Mex$145.00 | 15 |
Analyst Forecast: Target price is less than 20% higher than the current share price.